Bridgewater-based Cosette Pharmaceuticals announced Feb. 20 it entered into an agreement to acquire Mayne Pharma Group Ltd. in a $430 million deal. Mayne is an Australian-headquartered specialty ...

Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma Group Limited (Mayne Pharma, ASX: ...

Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. An update from Mayne ...

On 15 October 2025, the NSW Supreme Court found that US pharmaceutical company, Cosette Pharmaceuticals, Inc. did not validly terminate its $672 million takeover of ASX-listed Mayne Pharma Group ...

Shawn Patrick O’Brien stepped down as CEO and managing director, and Aaron Gray, currently Mayne Pharma’s chief financial officer, was appointed CEO. Robinson added, "The board welcomes Aaron to the ...

Australia's treasurer said the deal is not in the national interest, per a Reuters report. "Mayne Pharma is currently assessing its options and next steps," it said. The vast majority of Mayne ...

On 15 October 2025, the NSW Supreme Court found that US pharmaceutical company, Cosette Pharmaceuticals, Inc. (Cosette) did not validly terminate its $672 million takeover of ASX-listed Mayne Pharma ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Mayne Pharma Group ( (AU:MYX)) has issued ...

Cosette Pharmaceuticals Inc, which is backed by Avista Healthcare Partners and Hamilton Lane, has agreed to acquire Mayne Pharma, an Australian specialty pharmaceutical company, for $430 million.

Thank you. Thank you all for joining. My name is Shawn Patrick O'Brien, and I am the CEO and Managing Director of Mayne Pharma. Today, we are here to present our Financial Results for the Six Months ...

NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement ...